Analysts take a look at Circassia Pharmaceuticals Plc (LON:CIR) having this to say.

April 17, 2018 - By Maria Brooks

Circassia Pharmaceuticals Plc (LON:CIR) LogoInvestors sentiment increased to 1.02 in 2017 Q4. Its up 0.02, from 1 in 2017Q3. It is positive, as 7 investors sold Circassia Pharmaceuticals Plc shares while 37 reduced holdings. 12 funds opened positions while 33 raised stakes. 16.91 million shares or 4.21% more from 16.23 million shares in 2017Q3 were reported.
Teton Advsr owns 183,600 shares for 0.82% of their portfolio. Quantbot Technology Lp has 0.01% invested in Circassia Pharmaceuticals Plc (LON:CIR) for 1,300 shares. New York-based Gabelli Funds Ltd Llc has invested 0.27% in Circassia Pharmaceuticals Plc (LON:CIR). Elk Creek Partners Limited reported 287,887 shares. Ubs Asset Mgmt Americas holds 0% or 1,254 shares in its portfolio. First Mercantile Tru reported 3,746 shares or 0.04% of all its holdings. Wilen Investment Management has 0.31% invested in Circassia Pharmaceuticals Plc (LON:CIR) for 9,842 shares. New Jersey-based Quantum Capital Management Llc Nj has invested 2.44% in Circassia Pharmaceuticals Plc (LON:CIR). Price T Rowe Assocs Md stated it has 0.01% of its portfolio in Circassia Pharmaceuticals Plc (LON:CIR). Dimensional Fund Advsr Lp invested in 0.02% or 957,784 shares. Morgan Stanley has 35,329 shares for 0% of their portfolio. Advsr Asset Inc holds 0.03% or 41,690 shares. Millennium Mngmt Lc holds 0% of its portfolio in Circassia Pharmaceuticals Plc (LON:CIR) for 21,734 shares. Kennedy Capital holds 35,479 shares or 0.03% of its portfolio. Wells Fargo And Mn holds 0% of its portfolio in Circassia Pharmaceuticals Plc (LON:CIR) for 17,952 shares.

Circassia Pharmaceuticals Plc (LON:CIR) Ratings Coverage

Among 2 analysts covering Circassia Pharmaceuticals Plc (LON:CIR), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Circassia Pharmaceuticals Plc had 6 analyst reports since October 31, 2017 according to SRatingsIntel. The firm earned “Hold” rating on Thursday, March 1 by Peel Hunt. The rating was maintained by Peel Hunt with “Hold” on Tuesday, October 31. The rating was maintained by Peel Hunt on Thursday, February 1 with “Hold”. As per Monday, December 4, the company rating was maintained by Numis Securities. Peel Hunt maintained the stock with “Hold” rating in Wednesday, April 4 report. The stock of Circassia Pharmaceuticals Plc (LON:CIR) earned “Hold” rating by Peel Hunt on Thursday, January 4. Below is a list of Circassia Pharmaceuticals Plc (LON:CIR) latest ratings and price target changes.

04/04/2018 Broker: Peel Hunt Rating: Hold Old Target: GBX 130.00 Maintain
01/03/2018 Broker: Peel Hunt Rating: Hold Old Target: GBX 130.00 New Target: GBX 130.00 Maintain
01/02/2018 Broker: Peel Hunt Rating: Hold Old Target: GBX 130.00 New Target: GBX 130.00 Maintain
04/01/2018 Broker: Peel Hunt Rating: Hold Old Target: GBX 130.00 New Target: GBX 130.00 Maintain
04/12/2017 Broker: Numis Securities Rating: Buy Old Target: GBX 180.00 New Target: GBX 180.00 Maintain
31/10/2017 Broker: Peel Hunt Rating: Hold Old Target: GBX 130.00 New Target: GBX 130.00 Maintain

The stock decreased 0.11% or GBX 0.1 during the last trading session, reaching GBX 91.9. About 2,678 shares traded. Circassia Pharmaceuticals Plc (LON:CIR) has 0.00% since April 17, 2017 and is . It has underperformed by 11.55% the S&P500.

Circassia Pharmaceuticals plc, a specialty biopharmaceutical company, focuses on the development and commercialization of products for the treatment of asthma and chronic obstructive pulmonary disease . The company has market cap of 306.46 million GBP. It markets novel NIOX asthma management products directly to specialists in the United States, the United Kingdom, and Germany, as well as through a network of partners internationally. It currently has negative earnings. The companyÂ’s asthma products comprise Fliveo that targets substitution of Flixotide, which has approved in the United Kingdom, as well as developing Seriveo that targets direct substitution of Seretide.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.